Mostrar o rexistro simple do ítem
Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
dc.contributor.author | Pernas, Berta | |
dc.contributor.author | Grandal, Marta | |
dc.contributor.author | Pértega-Díaz, Sonia | |
dc.contributor.author | Cañizares, Angelina | |
dc.contributor.author | Castro-Iglesias, Ángeles | |
dc.contributor.author | Mena, Álvaro | |
dc.contributor.author | Rodríguez-Osorio, Iria | |
dc.contributor.author | Tabernilla, Andrés | |
dc.contributor.author | Pedreira, José D. | |
dc.contributor.author | Poveda, Eva | |
dc.date.accessioned | 2017-04-06T09:24:00Z | |
dc.date.available | 2017-04-06T09:24:00Z | |
dc.date.issued | 2015-12-24 | |
dc.identifier.citation | Pernas B, Grandal M, Pértega S, et al. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?. J Antimicrob Chemother. 2016;71(4):1051-1055 | es_ES |
dc.identifier.issn | 0305-7453 | |
dc.identifier.issn | 1460-2091 | |
dc.identifier.uri | http://hdl.handle.net/2183/18387 | |
dc.description.abstract | [Abstract] Objectives. The objective of this study was to evaluate the prevalence of blips and risk of virological failure (VF) among HIV-infected patients with sustained virological suppression (HIV-RNA <50 copies/mL) on ART. Methods. Newly diagnosed (2004–13) HIV-infected patients with sustained virological suppression on ART (minimum follow-up of 3 months) were identified. Risk of VF was evaluated according to different plasma HIV-RNA quantification values based on the limits of quantification/detection of current commercial assays (20 copies/mL). Kaplan–Meier and Cox proportional hazards models were used to compare the cumulative incidence of VF. Results. A total of 565 newly diagnosed HIV-infected patients were identified: 453 started ART and 354 achieved virological suppression. Prevalence of blips (isolated HIV-RNA ranging from 50 to 200 copies/mL) and VF (HIV-RNA ≥50 copies/mL) was 22.7% and 8.8%, respectively (mean follow-up of 42 months). Multivariate analysis identified differences between HIV-RNA values as an independent predictor of VF (P = 0.008); risk of VF was higher for patients with blips [HR 2.500 (95% CI 0.524–11.926)] and for those with at least three consecutive detected, but not quantified, HIV-RNA determinations (HIV-RNA <20 copies/mL) [HR 3.813 (95% CI 0.675–21.535)]. Moreover, only HIV-infected patients with at least three consecutive detected, but not quantified, HIV-RNA determinations showed a higher probability of virological rebound with >200 copies/mL [33.7% at 24 and 60 months versus <5% for other HIV-RNA values; HR 6.943 (0.728–66.261), P = 0.092]. Conclusions. Blips are frequent (22.7%) among HIV-infected patients with sustained virological suppression on ART. HIV patients with blips and at least three consecutive detected, but not quantified, HIV-RNA determinations (<20 copies/mL) had a higher risk of VF. These findings highlight the relevance of maintaining HIV-RNA levels below the limits of quantification of current assays (<20 copies/mL). | es_ES |
dc.description.sponsorship | Instituto de Salud Carlos III; CPII14/00014 | es_ES |
dc.description.sponsorship | Instituto de Salud Carlos III; PI10/02166 | es_ES |
dc.description.sponsorship | Instituto de Salud Carlos III; PI13/02266 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Oxford University Press | es_ES |
dc.relation.uri | https://doi.org/10.1093/jac/dkv433 | es_ES |
dc.rights | This is a pre-copyedited, author-produced version of an article accepted for publication in "Journal of Antimicrobial Chemotherapy" following peer review. The version of record is avaliable online at Oxford Academic | es_ES |
dc.subject | HIV | es_ES |
dc.subject | Follow-up | es_ES |
dc.subject | Plasma | es_ES |
dc.subject | Viremia | es_ES |
dc.subject | Virology | es_ES |
dc.subject | Blood HIV RNA | es_ES |
dc.subject | HIV infection | es_ES |
dc.title | Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART? | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.access | info:eu-repo/semantics/openAccess | es_ES |
UDC.journalTitle | Journal of Antimicrobial Chemotherapy | es_ES |
UDC.volume | 71 | es_ES |
UDC.issue | 4 | es_ES |
UDC.startPage | 1051 | es_ES |
UDC.endPage | 1055 | es_ES |
Ficheiros no ítem
Este ítem aparece na(s) seguinte(s) colección(s)
-
INIBIC-VC - Artigos [37]
-
INIBIC-ECB - Artigos [50]